Bradford, P. T., Devesa, S. S., Anderson, W. F. & Toro, J. R. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 113, 5064-5073

Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Blood (Impact Factor: 10.45). 03/2009; 113(21):5064-73. DOI: 10.1182/blood-2008-10-184168
Source: PubMed


There have been no prior large population-based studies focusing on cutaneous lymphomas (CL) in the United States. Using the Surveillance, Epidemiology and End Results (SEER) program data, we analyzed age-adjusted CL incidence rates (IRs) and survival rates by sex and race/ethnicity. There were 3884 CLs diagnosed during 2001-2005. Cutaneous T-cell lymphomas (CTCLs) accounted for 71% (age-adjusted incidence rate [IR] = 7.7/1 000 000 person-years), whereas cutaneous B-cell lymphomas(CBCLs) accounted for 29% (IR = 3.1/1 000 000 person-years). Males had a statistically significant higher IR of CL than females (14.0 vs 8.2/1 000 000 person-years, respectively; male-female IR ratio [M/F IRR] = 1.72; P < .001). CL IRs were highest among blacks and non-Hispanic whites (both 11.5/1 000 000 person-years), followed by Hispanic whites (7.9) and Asian/Pacific Islanders (7.1). The CTCL IR was highest among blacks (10.0/1 000 000 person-years), whereas the CBCL IR was highest among non-Hispanic whites (3.5). Over the past 25 years, the CL IR increased from 5.0/1 000 000 person-years during 1980-1982 to 14.3 during 2001-2003. During 2004-2005, the CL IR was 12.7. This recent apparent change could be incomplete case ascertainment or potential leveling off of IRs. CLs rates vary markedly by race and sex, supporting the notion that they represent distinct disease entities.

Download full-text


Available from: Susan Devesa, Mar 24, 2014
  • Source
    • "Reports of large-scale epidemiologic studies of the various subtypes of primary CTCLs and their relative frequencies have typically described population in developed countries. Data from developing countries are particularly scarce [4] [8], and studies of the epidemiological characteristics of primary CTCL in Iran are limited to one report that described a group of patients in Tehran [9]. Thus, the present study, which was conducted at the Cutaneous Lymphoma Center of Isfahan University of Medical Sciences, was the first to investigate the "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Primary cutaneous T-cell lymphomas (CTCLs) are a group of extranodal non-Hodgkin lymphomas that may be present in the skin without any evidence of extracutaneous disease. The aim of this study was to evaluate the epidemiological characteristics of primary CTCL in Isfahan, Iran. Method. A total of 95 patients who were diagnosed as having primary CTCL were recruited during a 10-year period (2003–2013) and were classified according to the new WHO-EORTC criteria. Results. The patient group consisted of 43 (44.8%) males and 53 (55.2%) females, which indicated a female predominance (M : F ratio 1 : 1.2). The mean age at the time of diagnosis was 41.78 ± 16.88 years (range: 7–84 years). Prior to diagnosis, the lesions had persisted for a mean of 8.34 ± 4.38 years (range: 0–55 years). The age at peak diagnosis was 20–40 years (43%). The most frequent subtypes were mycosis fungoides (MF) (88.5%). Four patients died from CTCL-related complications. Conclusions. The distinguishing epidemiologic characteristics of primary CTCL, particularly those MF, in Iran, are the absence of a male predominance and lower age at diagnosis. This is likely because of the characteristic ethnic group diversity and increased susceptibility among younger population.
    Full-text · Article · Dec 2014 · International Scholarly Research Notices
  • Source
    • "The most common type of cutaneous lymphoma is the cutaneous T-cell lymphoma (CTCL). Primary cutaneous B-cell lymphomas (CBCLs) with an incidence rate of approximately 3.1 per 1′000′000 persons and per year represent 20–25% of all cutaneous lymphomas [5], [6]. The most common CBCL subtypes are: primary cutaneous follicular lymphoma (PCFL), primary cutaneous marginal zone lymphoma (PCMZL), and diffuse large B-cell lymphoma, leg-type [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: While a variety of registered therapies exist for Cutaneous T Cell Lymphoma, no such therapy is available for Cutaneous B Cell Therapy. In this context we performed a phase II, open label, multicenter, non-comparative study to evaluate the efficacy and safety of repeated intra-lesional administrations of TG1042 (adenovirus-interferon-γ) in patients with relapsing primary cutaneous B-cell lymphomas (CBCL). Thirteen patients have been enrolled and received intralesional injections of TG1042 containing 5×10(10) viral particles into up to six lesions simultaneously. Injections were performed on days 1, 8 and 15 of each of four consecutive 28 day cycles. Eleven (85%) out of 13 enrolled patients showed an objective response after injections of TG1042. Seven patients (54%) exhibited complete and four (31%) displayed partial response. The median time to disease progression in the study population was 23.5 months (range 6.25 to 26+). Most commonly observed adverse events were minor to moderate flu-like symptoms, fatigue and injection site reactions. Our study showed that treatment with TG1042 was associated with a clinical benefit in the majority of the patients with relapsing CBCL, including tumor regression, a clinically meaningful duration of response and a good treatment tolerance. www.clinicaltrials.govNCT00394693.
    Full-text · Article · Feb 2014 · PLoS ONE
  • Source
    • "It is defined as a non-Hodgkin’s lymphoma of the skin without proof of extracutaneous manifestation at time of diagnosis. Mycosis fungoides accounts for 0.5% of all malignant lymphomas and for 44% of all cutaneous lymphomas,1 and has an incidence of 0.5/100.000/year.2 It occurs predominantly in men of middle and higher age.3 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Testicular neoplasms occur in more than 90% of cases, due to primary testicular germ cell tumors. Other entities are non germ cell tumors of the testis, testicular manifestation of lymphomas or metastases. International and interdisciplinary co-operation has led to the development of urological guidelines and to good therapeutic success for testicular neoplasms. The gold standard for treatment of a testicular neoplasm is the radical orchiectomy. However, for individual cases with suspected lymphoma, a treatment decision differing from the guidelines may be reasonable. We present the case of a 38-year-old man with testicular manifestation of a transformed mycosis fungoides, which is the most common form of cutaneous T-cell lymphoma.
    Full-text · Article · Jan 2014 · Rare tumors
Show more